HC Wainwright Issues Positive Forecast for RLAY Earnings

Relay Therapeutics, Inc. (NASDAQ:RLAY) – Equities research analysts at HC Wainwright lifted their Q1 2026 earnings per share (EPS) estimates for shares of Relay Therapeutics in a research report issued on Monday, March 23rd. HC Wainwright analyst R. Burns now expects that the company will earn ($0.36) per share for the quarter, up from their prior estimate of ($0.43). HC Wainwright currently has a “Buy” rating and a $19.00 target price on the stock. The consensus estimate for Relay Therapeutics’ current full-year earnings is ($2.55) per share. HC Wainwright also issued estimates for Relay Therapeutics’ Q2 2026 earnings at ($0.37) EPS, Q3 2026 earnings at ($0.38) EPS, Q4 2026 earnings at ($0.38) EPS and FY2026 earnings at ($1.49) EPS.

A number of other analysts have also weighed in on the company. Guggenheim upped their target price on Relay Therapeutics from $15.00 to $22.00 and gave the stock a “buy” rating in a report on Friday, March 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Relay Therapeutics in a research report on Friday, January 9th. Citizens Jmp lifted their target price on Relay Therapeutics from $15.00 to $17.00 and gave the company a “market outperform” rating in a research note on Tuesday, March 17th. Wells Fargo & Company boosted their target price on shares of Relay Therapeutics from $15.00 to $17.00 and gave the stock an “overweight” rating in a report on Tuesday, March 17th. Finally, Oppenheimer restated an “outperform” rating on shares of Relay Therapeutics in a report on Monday, March 16th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Relay Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $18.00.

Relay Therapeutics Stock Performance

NASDAQ RLAY opened at $9.60 on Wednesday. The company has a market cap of $1.72 billion, a PE ratio of -5.93 and a beta of 1.55. The firm’s 50 day moving average price is $9.02 and its 200-day moving average price is $7.55. Relay Therapeutics has a 52-week low of $1.77 and a 52-week high of $11.49.

Relay Therapeutics (NASDAQ:RLAY) last issued its earnings results on Thursday, February 26th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.38) by $0.06. The business had revenue of $7.00 million for the quarter, compared to the consensus estimate of $4.34 million.

Insider Buying and Selling at Relay Therapeutics

In other Relay Therapeutics news, CEO Sanjiv Patel sold 43,168 shares of the firm’s stock in a transaction that occurred on Tuesday, January 6th. The shares were sold at an average price of $7.82, for a total transaction of $337,573.76. Following the completion of the transaction, the chief executive officer directly owned 661,041 shares of the company’s stock, valued at approximately $5,169,340.62. This trade represents a 6.13% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Donald A. Bergstrom sold 18,895 shares of the company’s stock in a transaction on Tuesday, January 27th. The shares were sold at an average price of $7.62, for a total transaction of $143,979.90. Following the completion of the sale, the insider directly owned 422,733 shares in the company, valued at $3,221,225.46. This trade represents a 4.28% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 93,302 shares of company stock valued at $724,355. 4.87% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Relay Therapeutics

Institutional investors have recently modified their holdings of the stock. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Relay Therapeutics in the fourth quarter worth about $115,000. Seven Fleet Capital Management LP purchased a new stake in Relay Therapeutics in the 4th quarter worth approximately $618,000. Invesco Ltd. grew its stake in shares of Relay Therapeutics by 139.6% during the 4th quarter. Invesco Ltd. now owns 865,481 shares of the company’s stock worth $7,322,000 after purchasing an additional 504,291 shares during the period. EP Wealth Advisors LLC purchased a new position in shares of Relay Therapeutics during the 4th quarter valued at approximately $106,000. Finally, XTX Topco Ltd purchased a new position in shares of Relay Therapeutics during the 4th quarter valued at approximately $1,332,000. Hedge funds and other institutional investors own 96.98% of the company’s stock.

Key Headlines Impacting Relay Therapeutics

Here are the key news stories impacting Relay Therapeutics this week:

• Positive Sentiment: HC Wainwright materially raised 2026 EPS forecasts across quarters and for the full year, cutting projected losses (Q1: from ($0.43) to ($0.36); Q2: ($0.44)→($0.37); Q3: ($0.45)→($0.38); Q4: ($0.46)→($0.38); FY2026: ($1.78)→($1.49)). The firm keeps a “Buy” rating with a $19 price target — a clear positive analyst catalyst that can support further upside. HC Wainwright Forecasts Strong Price Appreciation for Relay Therapeutics (NASDAQ:RLAY) Stock
• Neutral Sentiment: Short-interest reports for March show zero shares short and nonsensical NaN changes across filings — likely a data/reporting anomaly. This item is not a reliable driver of price action unless updated with corrected figures.

Relay Therapeutics Company Profile

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.